Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.62 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457642 | 0.86 | KMT2A (0.47) | CYP4A11CYP4F2L3MBTL1NPC1RAB9A | |
| SCHEMBL3679325 | 0.84 | CYP4A11 (0.72) | CYP4A11CYP4F2LMNAMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL10866060 | 0.84 | L3MBTL1 (0.47) | CYP4A11CYP4F2L3MBTL1NPC1RAB9A | |
| SCHEMBL9661496 | 0.83 | SMN1; SMN2 (0.60) | L3MBTL1RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL9813840 | 0.83 | THRA (0.60) | CYP4A11CYP4F2L3MBTL1NPC1RAB9A | |
| SCHEMBL27498029 | 0.81 | LOXL2 (0.61) | L3MBTL1NPC1RAB9ALMNAMAPT | |
| SCHEMBL3871472 | 0.81 | KMT2A (0.46) | L3MBTL1NPC1RAB9ALMNAMAPT | |
| SCHEMBL8534234 | 0.81 | L3MBTL1 (0.54) | CYP4A11CYP4F2L3MBTL1NPC1RAB9A | |
| SCHEMBL3409184 | 0.81 | CYP4A11 (0.68) | CYP4A11CYP4F2LMNAMAPTALDH1A1 | |
| SCHEMBL12315535 | 0.80 | RAB9A (0.61) | L3MBTL1NPC1RAB9ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-2257315-B1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2009110984-A2 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1713512-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1713512-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Pharma Company (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005079391-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885L3MBTL1 2200/4885 |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885L3MBTL1 2200/4885 |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | MCOLN1, CNR1, SLC5A7 | CYP4A11 4854/4885CYP4F2 3814/4885L3MBTL1 2410/4885 |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | FABP7, MKI67, SLC5A7 | CYP4A11 4866/4885CYP4F2 3795/4885L3MBTL1 3294/4885 |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | MCOLN1, CNR1, SLC5A7 | CYP4A11 4854/4885CYP4F2 3814/4885L3MBTL1 2410/4885 |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885L3MBTL1 2200/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885L3MBTL1 2200/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885L3MBTL1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.